GW-870086

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C31H39F2NO6
Molecular Weight	559.6413
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@H](C)[C@](OC(=O)C3C(C)(C)C3(C)C)(C(=O)OCC#N)[C@@]1(C)C[C@H](O)[C@@]4(F)[C@@]2([H])C[C@H](F)C5=CC(=O)C=C[C@]45C

InChI

InChIKey=WUBKGTSFJSEIEM-NSHBDUGJSA-N

InChI=1S/C31H39F2NO6/c1-16-12-18-19-14-21(32)20-13-17(35)8-9-28(20,6)30(19,33)22(36)15-29(18,7)31(16,25(38)39-11-10-34)40-24(37)23-26(2,3)27(23,4)5/h8-9,13,16,18-19,21-23,36H,11-12,14-15H2,1-7H3/t16-,18+,19+,21+,22+,28+,29+,30+,31+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C31H39F2NO6
Molecular Weight	559.6413
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT01299610 | https://clinicaltrials.gov/ct2/show/NCT00945932

GW-870086 (now known as GSK 870086) was developed by GlaxoSmithKline as a glucocorticoid receptor agonist. Repeat inhaled doses of GW-870086 was studied in phase II clinical trial in patients with asthma. In addition, phase II clinical trial was investigated to determine the efficacy of GW-870086 ream formulation in subjects with moderate to severe atopic dermatitis. However, the development of this drug appears to have been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial.	2013 Dec	23991670
Discovery of GW870086: a potent anti-inflammatory steroid with a unique pharmacological profile.	2013 Jul	23639214
Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X.	2013 Mar 1	23462748

Patents

Sample Use Guides

In Vivo Use Guide

Dermatitis, Atopic: GW870086X cream formulation: GW870086 2.0%, GW870086 0.2% & Placebo each applied to a separate specific lesion for 21±2 days. Asthma: repeat inhaled doses of GW870086X

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:16:33 GMT 2023` Edited by `admin` on `Sat Dec 16 08:16:33 GMT 2023`
Record UNII	O891A2A3ZU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GW-870086

Common Name

English

ANDROSTA-1,4-DIENE-17-CARBOXYLIC ACID, 6,9-DIFLUORO-11-HYDROXY-16-METHYL-3-OXO-17-(((2,2,3,3-TETRAMETHYLCYCLOPROPYL)CARBONYL)OXY)-, CYANOMETHYL ESTER, (6.ALPHA.,11.BETA.,16.ALPHA.,17.ALPHA.)-

Systematic Name

English

GW870086

Code

English

GW870086X

Code

English

Code System Code Type Description

DRUG BANK

DB12322